Vascular Trial Associated Registry Pilot
Key facts
- Where
- Detroit and Grand Rapids, United StatesSee the 2 sites
- Phase
- Phase 4
Where in United States
- Henry Ford HospitalDetroit, United StatesContact: Sarah MeehanTaking people
- Corewell Health WestGrand Rapids, United StatesContact: Stephen C Orey, MSTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Corewell Health West
- Trial code
- NCT07076082
- Record updated
- 16 July 2026
- Original description
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.Read full original descriptionShow less
Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular Revascularization
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.
Inclusion: Age greater than or equal to 45 at time of enrollment; Patient is scheduled for a PVI or has recently had a PVI in the last 30 days; Patient data is being submitted to Fivos, who is acting as the data collection subcontractor for the VQI-PVI registry; Atherosclerotic vascular disease.
Exclusion: Patients on dual pathway inhibition (DPI) with low dose rivaroxaban (2.5mg twice a day) that are unable to stop these medications; Allergy to Clopidogrel; Allergy to aspirin; Nonatherosclerotic vascular disease; Patients with high bleeding risk (HBR) defined as:; History of major bleeding, active bleeding disorder, severe renal impairment (CrCl <30), concurrent anticoagulation, platelet count <100,000; Recent stroke (within 6 months); Current warfarin therapy or full dose therapeutic direct oral anticoagulants (DOAC); Patients who cannot consent for themselves; Patients unable to stop clopidogrel for other medical reasons; Patients undergoing open bypass at the same time as the peripheral transcutaneous angioplasty; Patients unwilling or unable to comply with standard of care follow-up visits; Pregnant women; Prisoners.